Sign In
Buy GNPX
$7.21
-0.460 (-6.00%)
At Close: Jul 20, 2026
Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer
10:13am, Thursday, 06'th May 2021
Genprex Inc (NASDAQ:GNPX) said that a major cancer research center in Houston has granted it an exclusive worldwide license for an additional portfolio of six patents and one patent application and re
Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung cancer
09:46am, Wednesday, 05'th May 2021
Genprex Inc (NASDAQ:GNPX) (FRA:2DE) has received centralized Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung c
Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA
11:40am, Tuesday, 04'th May 2021
Genprex Inc (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, announced that it has started clinical trial site recruitment for its upcoming
Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting
11:38am, Monday, 12'th Apr 2021
Genprex Inc (NASDAQ:GNPX) said its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemo
Wall Street starts in the red
11:38am, Monday, 12'th Apr 2021
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Ther
Genprex targets non-small cell lung cancer and diabetes via gene therapy
12:37pm, Tuesday, 06'th Apr 2021
Focused on developing life-changing therapies for patients with cancer and diabetes Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with
Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting
01:35pm, Tuesday, 30'th Mar 2021
Genprex Inc (NASDAQ:GNPX) said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer (NSLC), will be featured in tw
Genprex announces $25 million registered direct offering priced at-the-market
09:29am, Tuesday, 09'th Feb 2021
Genprex, Inc. (NASDAQ:GNPX) said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common st
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
08:30am, Tuesday, 09'th Feb 2021
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Genprex forms Clinical Advisory Board to support its oncology and diabetes development programs
04:42pm, Monday, 08'th Feb 2021
Genprex Inc (NASDAQ:GNPX) announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs. Comprised of preeminent clinical specialists, t
Genprex Recognizes World Cancer Day
08:30am, Thursday, 04'th Feb 2021
AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.
The 17 Stocks That Outperformed Tesla In 2020
11:54am, Thursday, 21'st Jan 2021
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqu
5 Biotech Stocks That Generated 1,000%+ Returns In 2020
10:30am, Saturday, 26'th Dec 2020
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from oppo
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
01:02pm, Thursday, 24'th Dec 2020
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces $12 million registered direct closing.
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants
01:15pm, Tuesday, 22'nd Dec 2020
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with
